Regen BioPharma, Inc.

Equities

RGBP

US75886M3007

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 14:58:23 03/06/2024 BST			5-day change	1st Jan Change
1.2 ^USD	+20.00%		+25.98%	+26.32%

04-24	Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
02-09	Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	CI

REGEN BIOPHARMA INC : Other Events (form 8-K)

August 10, 2022 at 11:24 am

Item 8.01 Other Events.

On August 9, 2022 KCL Therapeutics, Inc. ( a wholly owned subsidiary of Regen Biopharma, Inc. ) filed a provisional patent application with the United States Patent and Trademark Office covering methods, means and compositions of matter useful for treatment of cancer through enhancement of antitumor activity of chimeric antigen receptor (CAR) T cells through dedifferentiation of said cells. Chimeric antigen receptor (CAR)T cells are T cells that have been modified to attack specific antigens such as cancer cells. T cells are part of the immune system and develop from stem cells in the bone marrow.

Latest news about Regen BioPharma, Inc.

Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	04-24	CI
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	02-09	CI
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	01-19	CI
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	11-20	CI
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program	11-14	CI
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program	25/10/23	CI
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly	18/10/23	CI
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies	19/09/23	CI
Regen BioPharma, Inc. announced that it has received $0.14875 million in funding	11/09/23	CI
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	25/07/23	CI
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	18/04/23	CI
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	19/01/23	CI
Regen BioPharma, Inc. Announces Board Appointments	07/12/22	CI
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	15/11/22	CI
Regen BioPharma, Inc. Auditor Raises 'Going Concern' Doubt	14/11/22	CI
Regen BioPharma, Inc. Develops a Non-Exhaustible CAR-T Cell Therapeutic	10/11/22	CI
Regen BioPharma, Inc. Files Provisional Patent on Car-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer	05/10/22	CI
Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy	20/09/22	CI
Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy	13/09/22	CI
Regen Biopharma Develops Novel Means of Using Car-T Cell Immunotherapy to Attack Solid Tumors	25/08/22	CI
Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors	11/08/22	CI
Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine	26/07/22	CI
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22/07/22	CI
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	21/04/22	CI
Regen BioPharma, Inc. Announces Program to Fast-Track Its Checkpoint Inhibitor Program Utilizing Modified Mrna and Sirna Technologies	10/03/22	CI

Chart Regen BioPharma, Inc.

Duration

Period

More charts

Company Profile

Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients. tCellVax is a cell-based immunotherapy that stimulates the patientâs immune system through gene silencing of NR2F6.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGEN BIOPHARMA, INC.	+26.32%	4.17M
VERTEX PHARMACEUTICALS INCORPORATED	+13.95%	118B
REGENERON PHARMACEUTICALS, INC.	+13.52%	106B
BIONTECH SE	-2.08%	24.28B
ARGENX SE	+0.79%	21.96B
GENMAB A/S	-9.26%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.30%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+5.57%	13.63B
SAREPTA THERAPEUTICS, INC.	+30.29%	12.27B

Bio Therapeutic Drugs